Welcome to our dedicated page for Intelligent Bio Solutions SEC filings (Ticker: INBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
R&D milestones, biosensor patents, and drug-screening kit sales turn every Intelligent Bio Solutions Inc (INBS) filing into a technical maze. Stock Titan’s AI spots critical shifts—whether a new clinical study boosts revenue or an FDA update changes the regulatory timetable—so you no longer wade through hundreds of pages.
Track activity the moment it happens: Intelligent Bio Solutions insider trading Form 4 transactions and Intelligent Bio Solutions Form 4 insider transactions real-time appear on your dashboard seconds after EDGAR posts them. Need performance metrics? Open the Intelligent Bio Solutions quarterly earnings report 10-Q filing and read an AI snapshot that benchmarks fingerprint-sweat kit sales. Sudden news? The Intelligent Bio Solutions 8-K material events explained card tells you what changed and why.
Our platform offers comprehensive coverage of ALL filing types, each linked to a practical question:
- Is gross margin expanding? See the Intelligent Bio Solutions earnings report filing analysis inside the 10-Q.
- How is leadership paid? The Intelligent Bio Solutions proxy statement executive compensation section is distilled for quick review.
- Looking for long-term trends? The Intelligent Bio Solutions annual report 10-K simplified compiles five years of segment data.
Use these insights when understanding Intelligent Bio Solutions SEC documents with AI to monitor Intelligent Bio Solutions executive stock transactions Form 4 alerts, compare biosensor revenue over time, and prepare for upcoming catalysts. Real-time updates, AI-powered summaries, and expert context turn complex disclosures into clear answers.
Colony Bankcorp, Inc. (CBAN) – Form 4 insider transaction filed 07/02/2025.
CFO Derek Shelnutt reported an “F” transaction code, indicating the surrender of shares to satisfy withholding taxes upon the vesting of restricted stock.
- Shares withheld: 863 common shares at an implied value of $16.53 each (≈ $14.3 thousand).
- Post-transaction holdings: 9,357 shares held directly; 4,786 shares held indirectly through the 401(k) plan, for a total economic interest of 14,143 shares.
No derivative securities were reported, and there were no open-market purchases or sales. The filing is routine, reflecting tax-related share withholding rather than a discretionary sale, and does not materially alter insider ownership or signal a change in strategic outlook.
FAQ
What is the current stock price of Intelligent Bio Solutions (INBS)?
What is the market cap of Intelligent Bio Solutions (INBS)?
What core products does Intelligent Bio Solutions Inc offer?
How does the Intelligent Fingerprinting Products segment function?
What is the role of the Biosensor Platform Technology segment?
What distinguishes INBS's diagnostic approach from traditional methods?
Who are the primary users of Intelligent Bio Solutions' technologies?
How does Intelligent Bio Solutions maintain quality and reliability in its products?
How does INBS position itself within the competitive diagnostics market?
What industry-specific technologies and terms are integral to INBS's operations?
